Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: Journal of Medical Internet Research

Date Submitted: Sep 25, 2025

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Scalable, Low-Cost Augmented Reality Mobile Treatment for Spider Phobia: A Randomized Controlled Trial

  • Tara Donker; 
  • Ilja Cornelisz; 
  • Chris van Klaveren; 
  • Robin Niels Kok; 
  • Marieke Toffolo; 
  • Annemieke van Straten; 
  • Jamie Rhiannon Fehribach; 
  • Jean-Louis van Gelder

ABSTRACT

Background:

Background:

The global gap between demand for and access to evidence-based psychological treatment is large and accelarating. Smartphone-based augmented reality may help reduce this gap by improving accessbility to exposure-based therapies and reducing cost.

Objective:

Objective:

This study evaluated the effectiveness and user engagement of a fully automated smartphone-based augmented reality treatment for spider phobia symptoms.

Methods:

Methods:

We conducted a single-blind randomized controlled trial to evaluate the effectiveness of a fully automated smartphone-based AR cognitive behavioural therapy (CBT) app for spider phobia. A total of 113 adults (ages 18-65) with spider phobia symptoms were randomized to either the 6-week AR-CBT intervention (n = 56) or a wait-list control group (n = 57). All participants completed assessments remotely at baseline, post-intervention (6 weeks), and 3- and 12-month follow-ups. The intervention guided users through graded AR-based exposure to spiders via their own smartphone without therapist involvement. The primary outcome was change in spider phobia symptoms, measured by the Fear of Spiders Questionnaire. Secondary outcomes included anxiety, depression, app engagement, and in-app fear/disgust ratings. Analyses followed the intention-to-treat principle and were preregistered.

Results:

Results:

The intervention group showed significantly greater spider phobia reductions at post-test compared to controls (d = 1.25; 95% CI, 0.77–1.73; P< .001). Effects were maintained at 3-month- (d = 1.69) and 12-month follow-up (d = 1.64). Number needed to treat was 2.1. Longer session duration predicted greater improvement; practice session count did not. Overall dropout was 21%.

Conclusions:

Conclusions:

This study is the first to demonstrate that a fully automated mobile AR-CBT intervention, delivered in real-world settings without therapist involvement, can lead to strong and sustained reductions in spider phobia symptoms. By leveraging everyday smartphones and cutting-edge mobile AR technology, this intervention offers a low-threshold, widely accessible, scalable alternative for treating specific phobias. Clinical Trial: Prospectively Registered, Overview of Medical Research in the Netherlands, NL70238.029.19 (TrialNL9221) (https://onderzoekmetmensen.nl/nl/trial/27993).


 Citation

Please cite as:

Donker T, Cornelisz I, van Klaveren C, Kok RN, Toffolo M, van Straten A, Fehribach JR, van Gelder JL

Scalable, Low-Cost Augmented Reality Mobile Treatment for Spider Phobia: A Randomized Controlled Trial

JMIR Preprints. 25/09/2025:84727

DOI: 10.2196/preprints.84727

URL: https://preprints.jmir.org/preprint/84727

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.